Influence of histocompatibility genes on the clinical course of patients with relapsing-remitting multiple sclerosis treated with interferon beta-1a

被引：0
|
作者：
Fletcher, S.
Klein, T.
Pollak, L.
机构：
来源：
MULTIPLE SCLEROSIS | 2007年 / 13卷
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
引用
收藏
页码：S200 / S201
页数：2
相关论文
共 50 条
  • [41] COST-EFFECTIVENESS OF DACLIZUMAB VERSUS INTERFERON BETA-1A IN THE TREATMENT OF PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN THE UNITED STATES
    Rao, D.
    Heidari, E.
    Kamal, K. M.
    Dashputre, A. A.
    VALUE IN HEALTH, 2018, 21 : S206 - S206
  • [42] Evolution of anxiety according to coping strategy in patients with relapsing-remitting multiple sclerosis initiating treatment with IM interferon beta-1a
    Moreau, T
    Schmidt, N
    Malmaison, R
    Joyeux, O
    Bungener, C
    Souvignet, V
    NEUROLOGY, 2006, 66 (05) : A238 - A239
  • [43] COST-UTILITY ANALYSIS OF PEGYLATED INTERFERON BETA-1A VERSUS INTERFERONS BETA-1A AND BETA-1B IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN COLOMBIA
    Ordonez, J. E.
    VALUE IN HEALTH, 2017, 20 (05) : A193 - A194
  • [44] Clinical benefits of interferon beta-1a in relapsing-remitting MS:: a phase IV study
    Fernández, O
    Arbizu, T
    Izquierdo, G
    Martínez-Yélamos, A
    Gata, JM
    Luque, G
    de Ramón, E
    ACTA NEUROLOGICA SCANDINAVICA, 2003, 107 (01): : 7 - 11
  • [45] Alemtuzumab versus interferon beta 1a for relapsing-remitting multiple sclerosis
    Zhang, Jian
    Shi, Shengliang
    Zhang, Yueling
    Luo, Jiefeng
    Xiao, Yousheng
    Meng, Lian
    Yang, Xiaobo
    COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (11):
  • [46] Excerbations predict treatment failure in relapsing-remitting multiple sclerosis patients treated with beta-interferon
    Coret, E
    Bosca, I
    Pascual, A
    Landete, L
    Valero, C
    Casanova, B
    JOURNAL OF NEUROLOGY, 2004, 251 : 45 - 46
  • [47] Pharmacokinetics and pharmacodynamics of peginterferon beta-1a in patients with relapsing-remitting multiple sclerosis in the randomized ADVANCE study
    Hu, Xiao
    Cui, Yue
    White, Joleen
    Zhu, Ying
    Deykin, Aaron
    Nestorov, Ivan
    Hung, Serena
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015, 79 (03) : 514 - 522
  • [48] Clinical effects of interferon β in relapsing-remitting multiple sclerosis in view of natural course of the disease
    Pokryszko-Dragan, A
    Biliñska, M
    Gruszka, E
    Dubik-Jezierzañska, M
    MULTIPLE SCLEROSIS, 2004, 10 (7032): : S237 - S237
  • [49] Intramuscular interferon beta-1a, azathioprine, and corticosterold combination therapy in patients with relapsing-remitting multiple sclerosis: 5-year clinical efficacy results
    Havrdova, Eva
    Zivadinov, Robert
    Krasensky, Jan
    Dwyer, Michael
    Novakova, Iveta
    Dolezal, Ondrej
    Ticha, Veronika
    Svobodnik, Adam
    Seidl, Zdenek
    Houzvickova, Eva
    Horakova, Dana
    NEUROLOGY, 2007, 68 (12) : A277 - A277
  • [50] COST-EFFECTIVENESS OF GLATIRAMER ACETATE AND INTERFERON BETA-1A FOR RELAPSING-REMITTING MULTIPLE SCLEROSIS, BASED ON THE COMBIRX STUDY
    Darba, J.
    Kaskens, L.
    Sanchez-de la Rosa, R.
    VALUE IN HEALTH, 2013, 16 (07) : A623 - A623
12345